- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Christine Simmon Talks Uptake Patterns: Biosimilars vs Generics
Christine Simmon talks about whether or not biosimilar uptake will happen as rapidly as it did for generics at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Christine Simmon, JD, is the senior vice president of policy and strategic alliances for the Association for Accessible Medicines (AAM) and the executive director of AAM’s Biosimilars Council.
Transcript:
Will biosimilars be utilized to the same degree as generics?
To answer your question as to whether we will see the same level of uptake for biosimilars that we've seen in the generic realm, I think the jury's still out. These are more complex products. They are more costly to manufacture. They do require a higher level of investment and I think, most importantly, they are not, per se, interchangeable. I'm sure you know that the 90% dispensing rate that currently occurs in the United States for generic products is basically predicated on their automatic substitutability, which is, of course, a byproduct of being interchangeable. With biosimilars, the interchangeability that is unique to the United States is a separate designation that has to be achieved. So, I don't think we'll see [fast biosimilar uptake]. Certainly not as rapidly [as generics]. It's a longer-term play, and we'll have to wait and see.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
